Targeting the HGF/SF receptor c-met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells

The Prostate
Gaynor DaviesWen G Jiang

Abstract

Hepatocyte growth factor scatter factor (HGF/SF) elicits a number of biological activities including invasion and migration through activation of its tyrosine kinase receptor c-Met. Over expression of c-Met has been implicated in prostate cancer development and progression. This study examined the effect of a ribozyme transgene, designed to inhibit human c-Met expression, and its impact on in vitro invasion and migration in prostate cancer. A transgene (Met 560) consisting of U1 snRNA, hammerhead ribozyme, and antisense was cloned into a modified pZeoU1-EcoSpe vector and transfected into DU-145 cells. The effect of HGF/SF was tested on prostate cancer cells whose expression of c-Met had been blocked by way of a ribozyme transgene. Met 560 stable transfectants (DU-145(+/+)) manifested a complete loss of c-Met expression at mRNA and protein levels. In contrast, control plasmid (DU-145(+/-)) and wild-type DU-145 cells (DU-145(-/-)) had similar levels of c-Met expression. HGF/SF significantly increased the in vitro invasiveness (mean 47.71 +/- SE 7.75; P < 0.01 vs. control 24.14 +/- 1.34), and migration (mean 48.44 +/- SE 3.51; P < 0.01 vs. control 22.95 +/- 1.47) of DU-145(-/-) cells, respectively. Similarly, HGF/SF also increased...Continue Reading

References

Jul 19, 1990·Nature·Ermanno Gherardi, M Stoker
Jul 1, 1995·The Journal of Urology·L L PistersL W Chung
Jun 1, 2000·Breast Cancer Research and Treatment·S HiscoxW G Jiang
Dec 1, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·R AbounaderJ Laterra
Jul 8, 2003·International Journal of Cancer. Journal International Du Cancer·Gaynor DaviesWen G Jiang

Citations

May 12, 2005·Urology·Matthew R Smith, Joel B Nelson
Aug 19, 2006·Nucleic Acids Research·Aurel StratTony Giordano
Feb 7, 2013·Current Opinion in Oncology·Lorenza LandiFederico Cappuzzo
Mar 1, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kanwal P RaghavAna M Gonzalez-Angulo
Feb 12, 2010·Future Oncology·Luca Toschi, Federico Cappuzzo
Jul 12, 2011·Expert Opinion on Investigational Drugs·Xiangdong LiuPeggy A Scherle
Jun 14, 2008·Expert Opinion on Investigational Drugs·Xiangdong LiuPeggy A Scherle
Oct 23, 2012·The Urologic Clinics of North America·Yohann LoriotMartin E Gleave
Oct 8, 2005·Cell Motility and the Cytoskeleton·C M WellsG E Jones
Dec 21, 2004·Critical Reviews in Oncology/hematology·Wen G JiangToshikazu Nakamura
Nov 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amit GuptaShahrokh F Shariat
Oct 8, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jinlu DaiEvan T Keller

Related Concepts

Hammerhead ribozyme
Cell Motility
Neoplasm Invasiveness
Malignant Neoplasm of Prostate
Poly(A) Tail
Transfection
Tumor Cells, Cultured
Genetic Therapy, Somatic
Gene Expression Regulation, Neoplastic
Catalytic RNA

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.